Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

Art Still is one of the best defensive ends in University of Kentucky football history, becoming the No. 2 overall pick in ...

Alnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its ...

Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...

An Exeter Hospital hand surgeon's work is connecting carpal tunnel syndrome to a rare, life-threatening heart condition— and ...

Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary transthyretin-mediated amyloidosis.

Alnylam Pharmaceuticals' amyloidosis drug Amvuttra received Food and Drug Administration approval for an expanded indication.

Rece Hinds can build a nice career in the Cincinnati Reds’ outfield by showing the ability to adjust. Little did he know that ...